Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 369-374

  Price, Richard W ^a   Parham, Robin ^b   Kroll, Jing Lu ^c   Wring, Stephen A ^b   Baker, Brian ^b   Sailstad, Jeff ^d   Hoh, Rebecca ^a   Liegler, Teri ^a   Spudich, Serena ^a   Kuritzkes, Daniel R ^c   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Trimeris Inc   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Sailstad and Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; REPETITIVE DNA; RITONAVIR; TENOFOVIR; VIRUS RNA; GLYCOPROTEIN GP 41; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MALE; MOLECULAR CLONING; MOLECULAR PROBE; PATIENT COMPLIANCE; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; TANDEM MASS SPECTROMETRY; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE; WITHDRAWAL SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; BLOOD; BLOOD BRAIN BARRIER; CASE REPORT; CEREBROSPINAL FLUID; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; AIDS DEMENTIA COMPLEX; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; RNA, VIRAL; TANDEM MASS SPECTROMETRY;

EID: 47249109056     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003; 100:10598-10602.
2. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91:9770-9774.
3. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-186.
4. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
5. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004; 18:1787-1794.
6. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006; 43:60-64.
7. Stocker H, Kloft C, Plock N, et al. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother 2006; 50:667-673.
8. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
9. Chang D, Kolis SJ, Linderholm KH, et al. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. J Pharm Biomed Anal 2005; 38:487-496.
10. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37:385-390.
11. Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2005; 77:515-528.
12. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HTV-1-infected men. AIDS 2004; 18:1958-1961.
13. Hoggard PG, Sales SD, Kewn S, et al. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Antivir Chem Chemother 2000; 11:353-358.
14. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55:209-225.
15. Ray AS. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev 2005; 7:113-125.
16. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 2005; 79:7959-7966.
17. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 2005; 19:989-990.
18. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-1696.
19. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:544-552.